Treatment of malignant phaeochromocytoma, paraganglioma and carcinoid tumours with 131I-metaiodobenzylguanidine.

Journal article

131I-metaiodobenzylguanidine (MIBG) has been used for the therapy of neural crest tumours. We report our experience with this agent in nine patients (malignant phaeochromocytoma 2; malignant paragangliomas 3; malignant carcinoid tumours 4). Six patients had soft tissue metastases alone while three had both soft tissue and bone metastases. The follow-up period ranged from 8 to 110 months, the number of doses ranged from one to seven with 3.1 to 11.1 GBq per administration and a cumulative acti...

Expand abstract

Authors: Bomanji, J; Britton, K; Ur, E; Hawkins, L; Grossman, A

• Publication status: Published
• Journal: Nuclear medicine communications
• Volume: 14
• Issue: 10
• Pages: 856-861
• Publication date: 1993-10-01
• DOI: 10.1097/00006231-199310000-00004
• EISSN: 1473-5628
• ISSN: 0143-3636
• Language: English
• Keywords: Humans; Paraganglioma; Antineoplastic Agents; 3-Iodobenzylguanidine; Middle Aged; Iodobenzenes; Female; Carcinoid Tumor; Iodine Radioisotopes; Male; Pheochromocytoma; Aged; Combined Modality Therapy; Follow-Up Studies; Adult; Adrenal Gland Neoplasms